Log in

NASDAQ:SLNOSoleno Therapeutics Stock Price, Forecast & News

$4.00
-0.23 (-5.44 %)
(As of 05/25/2020 10:08 AM ET)
Add
Compare
Today's Range
$3.88
Now: $4.00
$4.36
50-Day Range
$2.19
MA: $3.05
$4.12
52-Week Range
$1.18
Now: $4.00
$4.39
Volume250,993 shs
Average Volume221,290 shs
Market Capitalization$178.84 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More
Soleno Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.33 per share

Profitability

Net Income$-30,770,000.00

Miscellaneous

Employees9
Market Cap$178.84 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

How has Soleno Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Soleno Therapeutics' stock was trading at $2.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SLNO stock has increased by 59.4% and is now trading at $4.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Soleno Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Soleno Therapeutics.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Soleno Therapeutics.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics Inc (NASDAQ:SLNO) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.07. View Soleno Therapeutics' earnings history.

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Shares of Soleno Therapeutics reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for SLNO?

3 brokerages have issued twelve-month price targets for Soleno Therapeutics' stock. Their forecasts range from $8.00 to $10.00. On average, they anticipate Soleno Therapeutics' share price to reach $9.33 in the next twelve months. This suggests a possible upside of 133.3% from the stock's current price. View analysts' price targets for Soleno Therapeutics.

Has Soleno Therapeutics been receiving favorable news coverage?

News stories about SLNO stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Soleno Therapeutics earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutSoleno Therapeutics.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 143,100 shares, an increase of 44.7% from the April 30th total of 98,900 shares. Based on an average daily trading volume, of 125,700 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.6% of the company's shares are short sold. View Soleno Therapeutics' Current Options Chain.

Who are some of Soleno Therapeutics' key competitors?

What other stocks do shareholders of Soleno Therapeutics own?

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the following people:
  • Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
  • Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
  • Mr. David D. O'Toole, Consultant (Age 60)
  • Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
  • Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vivo Capital LLC (4.52%), Geode Capital Management LLC (0.31%), BlackRock Inc. (0.19%), Oppenheimer & Co. Inc. (0.13%), Squarepoint Ops LLC (0.09%) and AE Wealth Management LLC (0.02%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Technology Partners Fund Vii L, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View institutional ownership trends for Soleno Therapeutics.

Which institutional investors are buying Soleno Therapeutics stock?

SLNO stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Geode Capital Management LLC, Oppenheimer & Co. Inc., Squarepoint Ops LLC, BlackRock Inc., and AE Wealth Management LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler, and Larry N Feinberg. View insider buying and selling activity for Soleno Therapeutics.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $4.00.

How big of a company is Soleno Therapeutics?

Soleno Therapeutics has a market capitalization of $178.84 million. The company earns $-30,770,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.